SCDRCTNCT05952817
Effect of Virtual Reality on Pain and Function in Children With Sickle Cell Disease: A Randomized Controlled Trial
A study testing virtual reality in people with SCD, run by Afnan Bkri at 1 site in Saudi Arabia.
Trial summary
Significance or rationale of the study: Virtual reality (VR) is a promising non-pharmacological pain management tool. It enhances motor function by promoting cortical reorganization and neuroplasticity. Read more about this study
- Who is it for?
- Ages 8 to 13 years
- Conditions the study is for
- SCD
- What is being tested?
- virtual reality
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteSaudi Arabia
- Study dates
- 1 Sep 2023to 29 Feb 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 13 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children aged between 8 and 13 years.
- Diagnosed with sickle cell disease (SCD), including homozygous SCA and other clinically confirmed variants.
- Medically stable and cleared by the treating physician to participate in mild activity.
- Receiving hydroxyurea as part of routine care.
- Able to follow simple instructions and communicate pain levels.
- Parental/legal guardian consent and child assent obtained.
Who cannot join
- Presentence of developmental, neurological, or genetic disorders.
- History of hip replacement or major orthopedic conditions affecting mobility.
- Current acute chest syndrome or unstable clinical condition.
- Visual or hearing impairments that would interfere with VR use.
- Participation in concurrent physiotherapy or rehabilitation programs.
- Previously enrolled in phase one of the current study (if applicable)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Virtual Reality on Pain, Physical Function, and Health-related Quality of Life in Children With Sickle Cell Disease: A Randomized Controlled Trial
Significance or rationale of the study:
Virtual reality (VR) is a promising non-pharmacological pain management tool. It enhances motor function by promoting cortical reorganization and neuroplasticity. Its multimodal biofeedback engages sensory and cognitive functions, making therapy interactive, motivating, and easy to understand. With strong rehabilitation potential, VR helps patients adapt to real-world movements (Laver, 2020). Initially used for procedural pain management, VR is now expanding into chronic pain rehabilitation by encouraging engagement with difficult or avoided movements (Griffin et al., 2020). Additionally, VR offers a dynamic alternative to traditional exercises, improving adherence and outcomes. Integrating entertainment into therapy can motivate children, enhancing their physical and psychological well-being. Recently, a few studies revealed an improvement in vaso-occlusive episodes (VOE) after VR treatment (Agrawal et al., 2019). However, efficacy studies are needed to assess VR's potential benefits. Additionally, data regarding VR's efficacy on daily pain, functional mobility, and HRQOL as complementary therapy are limited
Read the detailed description
- To investigate the effect of VR in reducing daily pain in children with SCD
- To evaluate the impact of VR on improving functional mobility in children with SCD.
- To examine the changes in PedsQL in children with SCD after engaging in VR experiences.
- To evaluate the safety and satisfaction of fully immersive VR therapy in children with
- Conditions
- SCD
- Being tested
- virtual reality
- Keywords
- Sickle Cell Disease, Virtual Reality, Numeric Rating Scale, Randomized Controlled Trial, Children, Health-Related Quality of Life, Pain, Functional Mobility
- Medical subject headings
- Anemia, Sickle Cell, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
virtual realityDevice
Virtual reality (VR) technology is a new medical intervention technique founded on the principle of distraction, providing real perceptual stimuli such as visual images, spatial sounds, tactile, and sensory feedback stimuli.(Zhang et al., 2022)
| Study group | Role | What they receive |
|---|---|---|
| virtual reality treatment | Experimental | Participants assigned to this arm received a fully immersive virtual reality (VR) exercise program. The intervention consisted of a series of interactive physical therapy games designed to improve functional mobility, joint movement, balance, and pain management. Sessions were conducted at home over five weeks using an Oculus Quest 2 headset and KindVR Aqua software. Each session lasted 15 minutes and was supervised weekly by a pediatric physical therapist through follow-up communication. Receives: Device: virtual reality |
| Standard Care Group | No intervention | Participants in this group received standard care without any additional VR-based interventions. They continued with their usual medical management and home routines as prescribed by their healthcare providers. No structured exercise or virtual therapy was provided during the study period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Intensity (Numeric Rating Scale - NRS)
Pain intensity was assessed using the validated Arabic version of the Numeric Rating Scale (NRS), which ranges from 0 (no pain) to 10 (worst imaginable pain). Participants were asked to rate their pain immediately before and after the VR session to measure the short-term analgesic effect of the intervention.
Measured: Baseline, Week 3, and Week 5
Secondary outcomes (2)
Health-Related Quality of Life (PedsQL)
The Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale was used to assess health-related quality of life in children aged 8-13 years. The Arabic validated version was administered at baseline, mid-intervention (week 3), and post-intervention (week 5). Higher scores indicate better quality of life across physical, emotional, social, and school functioning domains.
Measured: Baseline, Week 3, and Week 5
Functional Mobility (Timed Up and Go Test - TUG)
Functional mobility was measured using the Timed Up and Go (TUG) test. Participants were instructed to rise from a chair, walk 3 meters, turn around, walk back, and sit down. The total time taken to complete the task was recorded in seconds. Assessments were conducted at baseline, week 3, and week 5.
Measured: Baseline, Week 3, and Week 5
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jul 2023
- Study start1 Sep 2023
- Primary completion1 Feb 2024
- Study completion29 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for SCDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants were randomly assigned into two parallel groups following hospital discharge. The intervention group received a virtual reality (VR) program consisting of multiple sessions delivered over five weeks, while the control group continued with usual care. Both groups were followed at regular intervals, and outcome measures including pain intensity, physical function (Timed Up and Go), and health-related quality of life (PedsQL) were assessed at baseline, week 3, and week 5. The design followed a parallel assignment model without crossover between groups.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Afnan Bkri
- Sponsor type
- Other government
- Responsible party
- Sponsor-investigator, Afnan Bkri, Ministry of Health, Saudi Arabia
- Investigators
- afaf Ah shaheen, PHD, Study director, King Saud University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05952817
- Sponsor's protocol ID
- MohSaudiArabia1
- Other IDs
- Jazan health cluser ethics com
- Acronym
- RCT
- Status last verified
- Jun 2025
- First submitted
- 11 Jul 2023
- Last updated
- 18 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified IPD including pain scores and outcome measures will be available upon reasonable request with appropriate ethical approval. De-identified individual participant data (IPD), including pain scores and functional outcomes, will be made available upon reasonable request. Supporting documents such as the study protocol, statistical analysis plan, clinical study report, and analytic code will also be provided. Data will be shared through institutional data-sharing agreements and with approval from the responsible ethics committee. Availability is expected within 6 months following publication.
Publications
Agrawal AK, Robertson S, Litwin L, Tringale E, Treadwell M, Hoppe C, Marsh A. Virtual reality as complementary pain therapy in hospitalized patients with sickle cell disease. Pediatr Blood Cancer. 2019 Feb;66(2):e27525. doi: 10.1002/pbc.27525. Epub 2018 Oct 26.
PubMed 30362236Hassan Bakri AA, Algabbani MF, Farrag A, Elsayed W, Rezk MZA, Bindawas SM, Alhusaini AA, Shaheen AAM. Effect of fully immersive virtual reality on daily pain, functional mobility, and health-related quality of life in pediatric sickle cell disease: a single-blinded randomized clinical trial. Disabil Rehabil. 2026 Feb 10:1-15. doi: 10.1080/09638288.2026.2625551. Online ahead of print.
PubMed 41664928
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Virtual Reality on Pain, Physical Function, and Health-related Quality of Life in Children With Sickle Cell Disease: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05952817
- Acronym / sponsor ID
- RCT / MohSaudiArabia1
- Conditions
- SCD
- Keywords
- Sickle Cell Disease, Virtual Reality, Numeric Rating Scale, Randomized Controlled Trial, Children, Health-Related Quality of Life, Pain, Functional Mobility
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Afnan BkriOther government
- Study start
- 1 Sep 2023 (actual)
- Primary completion
- 1 Feb 2024 (actual)
- Study completion
- 29 Feb 2024 (actual)
- First posted
- 19 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Significance or rationale of the study:
Virtual reality (VR) is a promising non-pharmacological pain management tool. It enhances motor function by promoting cortical reorganization and neuroplasticity. Its multimodal biofeedback engages sensory and cognitive functions, making therapy interactive, motivating, and easy to understand. With strong rehabilitation potential, VR helps patients adapt to real-world movements (Laver, 2020). Initially used for procedural pain management, VR is now expanding into chronic pain rehabilitation by encouraging engagement with difficult or avoided movements (Griffin et al., 2020). Additionally, VR offers a dynamic alternative to traditional exercises, improving adherence and outcomes. Integrating entertainment into therapy can motivate children, enhancing their physical and psychological well-being. Recently, a few studies revealed an improvement in vaso-occlusive episodes (VOE) after VR treatment (Agrawal et al., 2019). However, efficacy studies are needed to assess VR's potential benefits. Additionally, data regarding VR's efficacy on daily pain, functional mobility, and HRQOL as complementary therapy are limited
Detailed description
- To investigate the effect of VR in reducing daily pain in children with SCD
- To evaluate the impact of VR on improving functional mobility in children with SCD.
- To examine the changes in PedsQL in children with SCD after engaging in VR experiences.
- To evaluate the safety and satisfaction of fully immersive VR therapy in children with
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Participants were randomly assigned into two parallel groups following hospital discharge. The intervention group received a virtual reality (VR) program consisting of multiple sessions delivered over five weeks, while the control group continued with usual care. Both groups were followed at regular intervals, and outcome measures including pain intensity, physical function (Timed Up and Go), and health-related quality of life (PedsQL) were assessed at baseline, week 3, and week 5. The design followed a parallel assignment model without crossover between groups.
| Arm | Type | Receives |
|---|---|---|
| virtual reality treatment | Experimental | Device: virtual realityParticipants assigned to this arm received a fully immersive virtual reality (VR) exercise program. The intervention consisted of a series of interactive physical therapy games designed to improve functional mobility, joint movement, balance, and pain management. Sessions were conducted at home over five weeks using an Oculus Quest 2 headset and KindVR Aqua software. Each session lasted 15 minutes and was supervised weekly by a pediatric physical therapist through follow-up communication. |
| Standard Care Group | No intervention | –Participants in this group received standard care without any additional VR-based interventions. They continued with their usual medical management and home routines as prescribed by their healthcare providers. No structured exercise or virtual therapy was provided during the study period. |
Who may qualify
- Ages
- 8 to 13 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Children aged between 8 and 13 years.
- Diagnosed with sickle cell disease (SCD), including homozygous SCA and other clinically confirmed variants.
- Medically stable and cleared by the treating physician to participate in mild activity.
- Receiving hydroxyurea as part of routine care.
- Able to follow simple instructions and communicate pain levels.
Key exclusion criteria (6 listed)
- Presentence of developmental, neurological, or genetic disorders.
- History of hip replacement or major orthopedic conditions affecting mobility.
- Current acute chest syndrome or unstable clinical condition.
- Visual or hearing impairments that would interfere with VR use.
- Participation in concurrent physiotherapy or rehabilitation programs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| virtual realityVirtual reality (VR) technology is a new medical intervention technique founded on the principle of distraction, providing real perceptual stimuli such as visual images, spatial sounds, tactile, and sensory feedback stimuli.(Zhang et al., 2022) | Device | virtual reality treatment |
Primary outcome
Pain Intensity (Numeric Rating Scale - NRS)
Time frame: Baseline, Week 3, and Week 5
Pain intensity was assessed using the validated Arabic version of the Numeric Rating Scale (NRS), which ranges from 0 (no pain) to 10 (worst imaginable pain). Participants were asked to rate their pain immediately before and after the VR session to measure the short-term analgesic effect of the intervention.
2 secondary outcomes
Health-Related Quality of Life (PedsQL)
Time frame: Baseline, Week 3, and Week 5
Functional Mobility (Timed Up and Go Test - TUG)
Time frame: Baseline, Week 3, and Week 5
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2025.
- Background: PubMed 30362236Agrawal AK, Robertson S, Litwin L, Tringale E, Treadwell M, Hoppe C, Marsh A. Virtual reality as complementary pain therapy in hospitalized patients with sickle cell disease. Pediatr Blood Cancer. 2019 Feb;66(2):e27525. doi: 10.1002/pbc.27525. Epub 2018 Oct 26.
- Derived from this study: PubMed 41664928Hassan Bakri AA, Algabbani MF, Farrag A, Elsayed W, Rezk MZA, Bindawas SM, Alhusaini AA, Shaheen AAM. Effect of fully immersive virtual reality on daily pain, functional mobility, and health-related quality of life in pediatric sickle cell disease: a single-blinded randomized clinical trial. Disabil Rehabil. 2026 Feb 10:1-15. doi: 10.1080/09638288.2026.2625551. Online ahead of print.
- Individual participant dataSharing planned: Yes. De-identified IPD including pain scores and outcome measures will be available upon reasonable request with appropriate ethical approval. De-identified individual participant data (IPD), including pain scores and functional outcomes, will be made available upon reasonable request. Supporting documents such as the study protocol, statistical analysis plan, clinical study report, and analytic code will also be provided. Data will be shared through institutional data-sharing agreements and with approval from the responsible ethics committee. Availability is expected within 6 months following publication.
Related trials for SCD
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Active, not recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Sickle Cell Disease, Hemolytic Anemia
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
afaf Ah shaheen, PHD study director
King Saud University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing virtual reality in people with SCD, run by Afnan Bkri at 1 site in Saudi Arabia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Intensity (Numeric Rating Scale - NRS) (time frame: Baseline, Week 3, and Week 5). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05952817, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2025.